Novo Nordisk's weight-loss drug has received US approval as a daily pill, marking the company's entry into the oral obesity treatment market. This achievement positions Novo Nordisk as the first to market, but rival Eli Lilly is reportedly close behind. The approval is expected to impact the pharmaceutical industry and obesity treatment market.